Evidence mapPaperPMID 39338169Full record

ReviewJournal of personalized medicine2024

Ovarian Hyperstimulation Syndrome (OHSS): A Narrative Review and Legal Implications.

Giuseppe Gullo, Gaspare Cucinella, Vukasin Stojanovic, Mirjana Stojkovic, Carmine Bruno, Adriana Vita Streva, Alessandra Lopez, Antonio Perino, Susanna Marinelli

Abstract readReview
In one paragraph

Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppe GulloDepartment of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF Unit, University of Palermo, 90146 Palermo, Italy.ORCID 0000-0003-4269-4269
Gaspare CucinellaDepartment of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF Unit, University of Palermo, 90146 Palermo, Italy.
Vukasin StojanovicEmergency Medicine Center of Montenegro, Faculty of Medicine, University of Montenegro, 81000 Podgorica, Montenegro.ORCID 0009-0000-8121-9845
Mirjana StojkovicClinic of Endocrinology, Diabetes and Metabolic Disorders, University Clinical Center of Serbia, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Carmine BrunoDepartment of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0002-3489-0238
Adriana Vita StrevaDepartment of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF Unit, University of Palermo, 90146 Palermo, Italy.
Alessandra LopezDepartment of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF Unit, University of Palermo, 90146 Palermo, Italy.ORCID 0000-0002-1041-3189
Antonio PerinoDepartment of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF Unit, University of Palermo, 90146 Palermo, Italy.
Susanna MarinelliSchool of Law, Polytechnic University of Marche, 60121 Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfertility is a highly meaningful issue with potentially life-changing consequences, and its incidence has been growing worldwide. Assisted reproductive technology (ART) has made giant strides in terms of treating many infertility conditions, despite the risk of developing ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication.

methodsThis narrative review draws upon scientific articles found in the PubMed database. The search spanned the 1990-2024 period. Search strings used included "OHSS" or "ovarian hyperstimulation" and "IVF" and "GnRH" and "hCG"; 1098 results were retrieved and were ultimately narrowed down to 111 suitable sources, i.e., relevant articles dealing with the condition's underlying dynamics, management pathways, and evidence-based criteria and guidelines, crucial both from a clinical perspective and from the standpoint of medicolegal tenability.

resultsThe following features constitute OHSS risk factors: young age, low body weight, and polycystic ovarian syndrome (PCOS), among others. GnRH antagonist can substantially lower the risk of severe OHSS, compared to the long protocol with a gonadotropin-releasing hormone (GnRH) agonist. However, a mild or moderate form of OHSS is also possible if the antagonist protocol is used, especially when hCG is used for the final maturation of oocytes. For women at risk of OHSS, GnRH agonist trigger and the freeze-all strategy is advisable. OHSS is one of the most frequent complications, with a 30% rate in IVF cycles.

conclusionProviding effective care for OHSS patients begins with early diagnosis, while also evaluating for comorbidities and complications. In addition to that, we should pay more attention to the psychological component of this complication and of infertility as a whole. Compliance with guidelines and evidence-based best practices is essential for medicolegal tenability.

Indexed as

assisted reproductive technology (ART)gonadotropin-releasing hormone (GnRH) antagonist protocolmedicolegal viabilityovarian hyperstimulation syndrome (OHSS)

Identifiers

PMID39338169
PMCPMC11433561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.